UNSPSC 51182018: Androstenediol

This classification denotes an anabolic steroid with the molecular formula C19H30O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 95PS51EMXY, chemically known as 3beta,17beta-dihydroxyandrost-5-ene but generally known as androstenediol, which bears US NIH Compound Identifier 10634. European Medicines Agency schedules Androstenediol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12899MIG. As of Q4 2014, ANDROSTENEDIOL remains the US FDA Preferred Term for this commodity.

Androstenediol bears US NLM identifiers UMLS ID C0524764 and NCI Concept Code C95979. SMILES: OC1C2(C(C3C(C4(C(=CC3)CC(O)CC4)C)CC2)CC1)C..

UNSPSC 51182018 Androstenediol, a Commodity code, covers the procurement of this steroid precursor compound by state and local government bodies, though recent state and local contracting activity under this specific code is not evident in available solicitation records. Androstenediol is a testosterone metabolite used in pharmaceutical formulations, research, and veterinary applications; state and local demand for this substance typically arises in public health laboratories, correctional-facility medical services, and educational research institutions. Because the code sits at the Commodity tier, it represents a narrow product line within the broader steroid and hormone family, and solicitations using this code would be expected from state health departments, county jail and prison systems, university research facilities, and state forensic or toxicology labs. The absence of recent posted opportunities under this code suggests either very low procurement volume, infrequent competitive solicitation cycles for this particular compound, or the likelihood that purchases occur through standing state contracts, cooperative purchasing vehicles, or direct awards to pharmaceutical suppliers without formal competitive notice.

Without recent state and local RFP, RFQ, IFB, or ITB records posted under UNSPSC 51182018, geographic concentration and specific recent opportunity details cannot be established from current market activity. Firms monitoring this code should expect solicitation patterns to cluster around states with large correctional systems or active pharmaceutical research universities, but the narrow product scope and apparent low procurement velocity mean this code warrants ongoing monitoring rather than active pursuit absent specific customer intelligence about upcoming laboratory or research facility upgrades or policy-driven increases in testing volume.